EU Fines Pharmaceutical Giants $22M

The European Commission has fined pharmaceuticals giants Johnson & Johnson and Novartis a combined $22 million for colluding to delay the entrance of a cheap generic form of a pain killer to the Dutch market.

AMSTERDAM (AP) — The European Commission has fined pharmaceuticals giants Johnson & Johnson and Novartis a combined $22 million for colluding to delay the entrance of a cheap generic form of a pain killer to the Dutch market.

In a statement, the Commission's antitrust chief, Joaquin Almunia, said the two companies "shockingly deprived patients in the Netherlands, including people suffering from cancer, from access to a cheaper version of this medicine."

The Commission found that after Johnson & Johnson's patent on a patch containing the drug Fentanyl expired in 2005, it paid Novartis to delay launching a generic version. The delay lasted 17 months, and was more profitable for both companies than competing honestly would have been.

J&J's fine was 10.7 million euros ($14.7 million), and Novartis' was 5.5 million euros.


More from MBTMag.com

Ford's Virtual Plant Mapping Technology

October Manufacturing Technology Orders Up

GM Stock Hits New High As Government Exit Nears

Explore more news here.

More in Home